Payment overview · 2025
General Payments
$1,056.41
55 reported records · 15 companies
Healthcare provider profile · identity verified
Amanda Kyle Brown, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LEESVILLE, LA · NPI 1275913360
Verified facts
What the public records show
CMS Open Payments records show Amanda Kyle Brown, FNP received $1,056.41 in general payments during 2025 across 55 reported records.
Lilly USA, LLC accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $173.47 | 16.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $166.41 | 15.8% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $160.45 | 15.2% | 6 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $159.88 | 15.1% | 7 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $65.90 | 6.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.34 | 5.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$55.10 | 5.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.58 | 4.6% | 3 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $35.50 | 3.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.88 | 2.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.37 | 2.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.63 | 2.2% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $20.37 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.00 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.53 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,056.41 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $160.45 | 6 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $159.88 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $145.36 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $145.36 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $66.43 | 4 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $65.90 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.16 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.16 | 5 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $55.10 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.58 | 3 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $40.82 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 318 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
318 | 80 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
359 | 74 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 595 | 182 |
| Ozempic | Semaglutide | 359 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 98 |
| Jardiance | Empagliflozin | 318 | 80 |
| Gabapentin | Gabapentin | 315 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 90 |
| Lisinopril | Lisinopril | 280 | 79 |
| Metformin Hcl | Metformin Hcl | 266 | 82 |
| Montelukast Sodium | Montelukast Sodium | 219 | 61 |
| Losartan Potassium | Losartan Potassium | 202 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 57 |
| Omeprazole | Omeprazole | 171 | 52 |
| Carvedilol | Carvedilol | 164 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 43 |
| Furosemide | Furosemide | 131 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 42 |
| Glipizide Er | Glipizide | 126 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 33 |
| Ezetimibe | Ezetimibe | 103 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 29 |
| Trazodone Hcl | Trazodone Hcl | 100 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 37 |
| Mounjaro | Tirzepatide | 93 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 29 |
| Famotidine | Famotidine | 89 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 27 |
| Alprazolam | Alprazolam | 82 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 29 |
| Potassium Chloride | Potassium Chloride | 79 | 27 |
| Eliquis | Apixaban | 76 | 15 |
| Meloxicam | Meloxicam | 75 | 28 |
| Fenofibrate | Fenofibrate | 69 | 19 |
| Januvia | Sitagliptin Phosphate | 68 | 17 |
| Tradjenta | Linagliptin | 68 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 28 |
| Nifedipine Er | Nifedipine | 64 | 24 |
| Fluconazole | Fluconazole | 63 | 24 |
| Azithromycin | Azithromycin | 62 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 19 |
| Alendronate Sodium | Alendronate Sodium | 58 | 21 |
| Levetiracetam | Levetiracetam | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 16 |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 15 |
| Pregabalin | Pregabalin | 49 | 15 |
| Celecoxib | Celecoxib | 47 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 45 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 14 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 13 |
| Novolog Flexpen | Insulin Aspart | 39 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 38 | 28 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 22 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Finasteride | Finasteride | 34 | 13 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 34 | suppressed |
| Prednisone | Prednisone | 34 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 11 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 17 |
| Atenolol | Atenolol | 31 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Torsemide | Torsemide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 15 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 11 |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cabergoline | Cabergoline | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,056.41 · 55 records | Lilly USA, LLC | AUSTEDO XR, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, JARDIANCE, Kerendia, Korlym, MINIMED 780G, MOUNJARO, NALOCET, OTEZLA, Omnipod, PROLATE, REPATHA, SYNTHROID, TANLOR, TEPEZZA, TZIELD, UBRELVY, VRAYLAR, Wegovy, Yorvipath, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error